Clinical trial of combination therapy with ozagrel and vinpocetine in the treatment of stroke patients
10.13699/j.cnki.1001-6821.2017.13.003
- VernacularTitle:奥扎格雷注射剂联合长春西汀注射剂治疗脑卒中患者的临床研究
- Author:
Hai-Yan GU
1
;
Guo-Juan DING
;
Xing-Yue HU
Author Information
1. 宁波市康复医院神经康复二科
- Keywords:
ozagrel;
vinpocetine;
stroke;
platelet activation
- From:
The Chinese Journal of Clinical Pharmacology
2017;33(13):1177-1180
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical efficacy and safety of combination therapy with ozagrel and vinpocetine in treatment of stroke.Methods A total of 120 stroke patients were randomly divided into treatment group (60 cases) and control group (60 cases).Both groups were given conventional treatment.The control group received intravenous infusion of ozagrel sodium 160 mg qd.The treatment group was given intravenous drip of vinpocetine 30 mg qd.The treatment lasted for 14 days.The clinical efficacy and Activity of Daily Living Scale (ADL),National Institutes of Health Stroke Scale(NIHSS) score of the two groups were compared.The fibrinogen,prothrombin time,activated partial thromboplastin time (APTT),platelet count,platelet distribution width,mean platelet volume and adverse drug reactions in 2 groups were compared.Results After treatment,the total effective rates of the treatment group and the control group were 91.67％ (55/60 cases) and 76.7％ (46/60 cases),the difference was statistically significant (P ＜0.05).After treatment,the ADL scores of the treatment group and the control group were (58.53 ±9.37),(53.52 ±8.80),the NIHSS scores were (6.67 ±2.12),(8.28±2.83),the PDW were (17.41 ± 3.60)％,(20.52 ± 3.89)％,the MPV were (7.12 ±0.43)％,(8.17 ±0.52)％,the fibrinogen were (3.43 ±0.59),(3.75 ±0.68)g · L-1,and the differences between the groups were statistically significant (P ＜ 0.05).The main adverse drug reactions of the treatment group were purpura (2 cases) and rash (1 case),while the adverse drug reaction in the control group was rash (1 case).The incidences of adverse drug reactions in the treatment group and the control group were 5.00％ (3/60 cases) and 1.67％ (1/60 cases),without statistically significant difference (P ＞ 0.05).Conclusion Ozagrel combined with vinpocetine could inhibit platelet activation and improve neural function with high safety in the treatment of stroke.
